Vitamin D(3) analogues were shown to be beneficial for osteoporosis and other indications, but their narrow therapeutic window between efficacy and hypercalcemia has limited their clinical utility. A nonsecosteroidal, tissue-selective, orally bioavailable, vitamin D receptor (VDR) ligand was ascerta
Identification and characterization of a novel nonsecosteroidal vitamin D receptor ligand
β Scribed by Fang Chen; Qin Su; Maricel Torrent; Nan Wei; Norbert Peekhaus; Daniel McMasters; John Fisher; Helmut Glantschnig; Paul Hodor; Osvaldo Flores; Alfred Reszka
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 275 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
β¦ Synopsis
Vitamin D receptor (VDR)
and its ligands play important roles in mineral/skeletal homeostasis, cell proliferation/differentiation, and modulation of immune responses. VDR ligands make attractive candidates for the treatment/prevention of osteoporosis, psoriasis, and cancer. The major issue with current analogs is hypercalcemia. As nonsteroidal therapeutic agents with fewer side effects have been made for androgen and estrogen receptors, nonsecosteroidal VDR ligands possessing beneficial effects may also be possible. Here we present a novel podocarpic acid-based nonsecosteroidal VDR ligand (VDRL-1). VDRL-1 bound to VDR with a Ki of $1.3 mM in competition binding assays. Data from binding and molecular docking suggest that VDRL-1 interacts with the same binding pocket as 1a,25-(OH) 2 vitamin D 3 (1,25-D 3 ). In cell-based transcription assays, VDRL-1 reached the same maximal activity as 1,25-D 3 , albeit with an EC 50 $1.0 mM. Likewise, VDRL-1 was a full agonist in suppressing proliferation of several human cancer cells. Microarrays demonstrated that VDRL-1 exerted a near identical expression pattern to that of 1,25-D 3 in several human cancer cells. Taqman analysis of known and novel VDR-regulated genes showed that VDRL-1 was a full agonist on osteocalcin (OC), CYP24A1, and other genes. It exerted partial agonist activity on G0/ G1 switch gene 2 (G0S2). Furthermore, VDRL-1 could be a full or partial agonist of calcium transporter 1 (TRPV6) expression and partially antagonized 1,25-D 3 in cells where it partially regulated TRPV6. Thus, the current study describes a novel nonsecosteroidal VDR ligand that behaves mostly like 1,25-D 3 , but possesses unique characteristics.
π SIMILAR VOLUMES
The sequences from several independent cDNA clones encoding the chicken vitamin D receptor as well as primer extension assay have clearly delineated the 5Π terminus and the transcriptional start site. Screening a chicken genomic library produced genomic clones containing vitamin D receptor (VDR) gen
The asialoglycoprotein receptor, the hepatic binding lectin for galactose-terminated glycoproteins, has been isolated and characterized from human, rabbit and rat liver. Several recent studies have shown the existence of the same receptor in murine liver. However, the biochemical structure of the re